Results 101 to 110 of about 2,224,846 (160)

Erlotinib completely reverses topotecan-resistance in multidrug resistant cancer cells overexpressing breast cancer resistant protein 1

, 2019
[[abstract]]Erlotinib inhibits the ATP-binding site of the tyrosine kinase associated with the epidermal growth factor receptor. We have recently demonstrated that gefitinib, a structurally similar receptor tyrosine kinase inhibitor, inhibited functions ...
Yang, CH;Yang, CS;Huang, CJ;Cheng, AL;Whang-Peng, J;Yang, PC
core  

[Retracted] Exosome‑mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non‑small cell lung cancer. [PDF]

Int J Oncol, 2023
Zhang W, Cai X, Yu J, Lu X, Qian Q, Qian W.   +5 more
europepmc   +1 more source

Erratum: Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas: Erratum. [PDF]

Theranostics, 2023
Lei HM, Zhang KR, Wang CH, Wang Y, Zhuang GL, Lu LM, Zhang J, Shen Y, Chen HZ, Zhu L.   +9 more
europepmc   +1 more source

Inhibition of miR-185-3p Confers Erlotinib Resistance Through Upregulation of PFKL/MET in Lung Cancers. [PDF]

Front Cell Dev Biol, 2021
Li K, Zhu X, Yuan C.
europepmc   +1 more source

M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way. [PDF]

J Exp Clin Cancer Res, 2021
Li K, Peng ZY, Gao S, Wang QS, Wang R, Li X, Xiao GD, Zhang J, Ren H, Tang SC, Sun X.   +10 more
europepmc   +1 more source

Erratum: Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum. [PDF]

Theranostics, 2021
Dong JK, Lei HM, Liang Q, Tang YB, Zhou Y, Wang Y, Zhang S, Li WB, Tong Y, Zhuang G, Zhang L, Chen HZ, Zhu L, Shen Y.   +13 more
europepmc   +1 more source

Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib

, 2013
Elevated expression and activity of the epidermal growth factor receptor (EGFR) is associated with development and progression of head and neck cancer (HNC) and a poor prognosis. Clinical trials with EGFR tyrosine kinase inhibitors (e.g., erlotinib) have
Stuart, L., Redfern, A., Zhang, P., Giles, K., Leedman, P., Epis, M., Goodall, G., Candy, P., Kalinowski, F.   +8 more
core   +1 more source

Summary of thirteen patients acquired resistance to erlotinib.

, 2013
Time on erlotinib*, Time to progression after erlotinib therapy; Response#, Response to erlotinib; del,deletion; Adeno, adenocarcinoma. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.
Xiaoju Zhang (387133), Xitao Ma (387136), Qiyu Qian (387135), Zhaogang Dong (146628), Yi Kang (387134), Guangzhi Liu (294879)   +5 more
core   +1 more source

Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer. [PDF]

Biochem Pharmacol, 2021
Pal AS, Bains M, Agredo A, Kasinski AL.
europepmc   +1 more source

Re-use of erlotinib in a patient using osimertinib after erlotinib, case report

, 1995
Introduction Most patients with non-small-cell lung cancer tumors that have epidermal growth factor receptor (EGFR) mutations have deletion mutations in exon 19 or exon 21, or both.In recent years, targeted therapies in lung cancer have increased ...
Ünal, Vahdet, Gursoy, Pinar
core   +1 more source